Search

EP-4736840-A2 - LACTOBACILLUS PLANTARUM FOR SKIN CARE

EP4736840A2EP 4736840 A2EP4736840 A2EP 4736840A2EP-4736840-A2

Abstract

The present invention relates to microorganisms for use in the treatment and/or prevention of skin conditions by topical application. In particular, the microorganisms are for use in the treatment and/or prevention of loss of skin barrier function, inflammatory skin conditions and/or growth of pathogenic microorganism. The invention further relates to pharmaceutical or cosmetic compositions or products comprising the microorganisms. Provided is also a cosmetic use of the microorganisms or compositions for application on the skin and a cosmetic method, in particular to improve the appearance of the skin.

Inventors

  • PESARO, Manuel
  • STUHLMANN, DOMINIK
  • GARBE, Lisa
  • SCHMAUS, GERHARD
  • HOLMGREN, KERSTIN
  • LARSSON, NIKLAS

Assignees

  • Symrise AG
  • PROBI AB

Dates

Publication Date
20260506
Application Date
20190626

Claims (15)

  1. Microorganism or mixture comprising or consisting of two microorganisms for use in the treatment and/or prevention of skin conditions by topical application, wherein the microorganism(s) is/are selected from the group consisting of Lactobacillus plantarum HEAL 19 (DSM 15313) and Lactobacillus plantarum HEAL 99 (DSM 15316).
  2. Microorganism or mixture for use according to claim 1, wherein the microorganism(s) has/have been subjected to a heat-treatment and are preferably attenuated or dead microorganisms having an intact physical structure.
  3. Microorganism or mixture for use according to claim 1 or 2, wherein the skin condition(s) is/are loss of skin barrier function, inflammatory skin conditions and/or growth of pathogenic microorganisms, preferably wherein the skin condition is selected from the group consisting of atopic dermatitis, microbial infection, dry skin, itchy skin, sensitive skin, atopic skin, inflammation of the skin, microbial dysbiosis, rosacea, psoriasis, rash and acne.
  4. Preparation comprising or consisting of one or a mixture of two microorganism(s) selected from the group consisting of Lactobacillus plantarum HEAL 19 (DSM 15313) and Lactobacillus plantarum HEAL 99 (DSM 15316) and a carrier, wherein the preparation is a particulate preparation, in particular a granulate or a powder.
  5. Preparation according to claim 4, wherein the microorganism(s) has/have been subjected to a heat-treatment and are preferably attenuated or dead microorganisms having an intact physical structure.
  6. Preparation according to claim 4 or 5, wherein the carrier is selected from the group consisting of inulin, starch, gummi arabicum, whey proteins, skim milk powders and maltodextrin as well as combinations thereof, preferably maltodextrin.
  7. Preparation according to any of claims 4 to 6, wherein the ratio of microorganism(s) to carrier is in the range from 1 : 9 to 3 : 7, preferably 1.5 : 8.5 to 2.5 to 7.5 and/or wherein the preparation comprises 10 to 30 wt.-% microorganism(s) and 70 to 90 wt.-% of the carrier, preferably 15 to 25 wt.-% microorganism(s) and 75 to 85 wt.-% of the carrier, in each case with respect to the total weight of the preparation.
  8. Method for producing a preparation comprising or consisting of one or a mixture of two microorganism(s) selected from the group consisting of Lactobacillus plantarum HEAL 19 (DSM 15313) and Lactobacillus plantarum HEAL 99 (DSM 15316) and a carrier, preferably a preparation according to any of claims 4 to 7, comprising the step(s): (i) providing one or a mixture of two microorganism(s) selected from the group consisting of Lactobacillus plantarum HEAL 19 (DSM 15313) and Lactobacillus plantarum HEAL 99 (DSM 15316); (ii) optionally, subjecting the microorganism(s) of step (i) to a heat-treatment, preferably at a temperature in the range of 60 to 121 °C for 1 second to 120 minutes; (iii) combining the microorganism(s) from step (i) or (ii) with a carrier and further processing the combination to obtain a granulate or a powder, preferably by freeze-drying, spray-drying or granulating.
  9. Pharmaceutical or cosmetic composition or pharmaceutical or cosmetic product for topical application to the skin comprising one or a mixture of two microorganism(s) selected from the group consisting of Lactobacillus plantarum HEAL 19 (DSM 15313) and Lactobacillus plantarum HEAL 99 (DSM 15316) or comprising a preparation according to any of claims 4 to 7, wherein the total amount of the microorganism(s) is sufficient for treating and/or preventing skin conditions, in particular inflammatory skin conditions, loss of skin barrier function, and/or growth of pathogenic microorganisms, preferably wherein the total amount of the microorganism(s) is in the range from 0.01 to 5 % dry weight, preferably from 0.02 to 1 % dry weight, in each case with respect to the total weight of the composition, and/or wherein the total amount of the microorganism(s) is at least 10^8, preferably 5 x 10^8 cells or at least 10^11 cells per gram of the total composition, such as in the range from 10^8 to 5 x 10^10, preferably from 10^9 to 10^10 cells per gram of the total composition.
  10. Pharmaceutical or cosmetic composition or product according to claim 9, wherein the composition or product is selected from the group consisting of oil in water or water in oil emulsion, ointment, crème, lotion and gel, preferably wherein the composition or product further comprises one or more component(s) selected from the group consisting of carriers, excipients and further active ingredients.
  11. Method for producing a pharmaceutical or cosmetic composition or product, preferably a pharmaceutical or cosmetic composition or product according to claim 9 or 10, comprising the steps: (i) providing one or a mixture of two microorganism(s) selected from the group consisting of Lactobacillus plantarum HEAL 19 (DSM 15313) and Lactobacillus plantarum HEAL 99 (DSM 15316), preferably wherein the microorganism(s) has/have been subjected to a heat-treatment and are preferably attenuated or dead microorganisms having an intact physical structure, or providing a preparation according to any of claims 4 to 7 or a preparation produced by a method according to claim 8, and (ii) combining the microorganism(s) or the preparation of step (i) with one or more substances selected from carriers, excipients and further active ingredients to obtain a pharmaceutical or cosmetic composition or product.
  12. Cosmetic use of a microorganism or mixture comprising or consisting of two microorganisms for topical application on the skin, in particular to improve the appearance of the skin, wherein the microorganism(s) is/are selected from the group consisting of Lactobacillus plantarum HEAL 19 (DSM 15313) and Lactobacillus plantarum HEAL 99 (DSM 15316), preferably wherein the microorganism(s) has/have been subjected to a heat-treatment and/or are attenuated or dead micro-organisms having an intact physical structure.
  13. Cosmetic use according to claim 12 for reducing or preventing skin irritation, dry skin, rash, acne, and/or skin aging.
  14. Cosmetic use according to claim 12 or 13, wherein the microorganism(s) are used in the form of a preparation according to any of claims 4 to 7 or a preparation produced by a method according to claim 8.
  15. Cosmetic method to improve the appearance of the skin, in particular to reduce or prevent skin irritation, dry skin, rash, acne and/or skin aging, comprising the step i) applying a microorganism or a mixture comprising or consisting of two microorganisms topically to the skin, wherein the microorganism(s) is/are selected from the group consisting of Lactobacillus plantarum HEAL 19 (DSM 15313) and Lactobacillus plantarum HEAL 99 (DSM 15316), or applying a preparation according to any of claims 4 to 7 or preparation produced by a method according to claim 8 or a cosmetic composition or product according to claim 9 or 10 to the skin, preferably wherein the microorganism(s) has/have been subjected to a heat-treatment and/or are attenuated or dead microorganisms having an intact physical structure.

Description

The present invention relates to microorganisms for use in the treatment and/or prevention of skin conditions by topical application, wherein the microorganisms are selected from the group consisting of Lactobacillus plantarum HEAL 19 (DSM 15313) and Lactobacillus plantarum HEAL 99 (DSM 15316). In particular, the microorganisms are for use in the treatment and/or prevention of loss of skin barrier function, inflammatory skin conditions and/or growth of pathogenic microorganism. The invention further relates to a particulate preparation comprising the microorganism(s) and a carrier as well as pharmaceutical or cosmetic compositions or products comprising the microorganisms. Provided is also a cosmetic use of the microorganisms or compositions for application on the skin and a cosmetic method, in particular to improve the appearance of the skin and/or prevent body odor. Probiotics are well known to improve gut well-being, attributed to the rise of the gut-brain axis correlations, alleviate lactose intolerance, are beneficial in vaginal or urogenital infection treatment or prevent inflammatory bowel disease. Especially Lactobacillus sp. has a safe and long tradition in food fermentation processes. In contrast to the gut, little is known about the interactions between epidermis, skin microbiota and environmental microorganisms. Nowadays more and more studies show that probiotics exert other health promoting effects including skin health. Bifidobacteria and Lactic acid bacteria are the most common types of probiotics used and the area of skin care using these has been actively developed over the last years. However, not all probiotic strains show beneficial effects on skin and single strains are rarely mentioned. And even if, the balance between an anti-inflammatory or other effects as an active component in a cosmetic composition and the non-causing of any pro-inflammation side effects by the microorganism itself needs to be given. The skin is continuously exposed to bacteria, microorganisms and potential pathogens. To avoid infections or invasion of these pathogenic bacteria the skin has developed multifaceted defense strategies. Beside the physical and chemical barrier of the stratum corneum it includes the constitutive and inductive AMP barrier, which is essential in this context (Harder et al. 2013, Wiesner and Vilcinskas 2010). Antimicrobial peptides (AMP) are a diverse and abundant group of molecules. Characteristic are the small size, amino acid composition, amphipathicity and/or cationic charge. On the basis of their amino acid composition they are often divided into characteristic subgroups. Their diversity of antimicrobial potential and mechanism of action is as diverse as their structure and composition. They can be detected in various tissues and cell types of invertebrates, animal species and plants (Brogden 2005, Zasloff 2002). In human skin they serve as first defense line, as they are active against a broad spectrum of Gram positive and Gram negative bacteria, fungi, eukaryotic parasites and/or viruses (Brown and Hancock 2006). The AMP expression can be up-regulated in response to various environmental stimuli like contact to pathogens or intracellular inflammation pathways. Commensal and pathogenic bacteria differ in their ability to induce AMP expression and activate different signaling pathways in human skin to innate human immunity. Little is known about the specific interactions between both. Beta-Defensins for example are upregulated by various stimuli of inflammation and/or infections, like interleukin 1 or bacterial lipopolysaccharide (Chung and Dale 2004). Mahe et al. (US2009/0035294 A1) disclose that LPS from Vitreoscilla filiformes comprising Lipid A has the ability to stimulate the expression of AMPs in keratinocytes without having pathogenic activity. It is known that the skin microbiome can play a key role in various skin diseases and/or health conditions. The complexity and inter/intra-individual variety of the microbiome as well as the difficulties in characterizing, categorizing, and analyzing are the challenges in understanding interactions and developing topical therapeutic and/or diagnostic applications and/or treatments that helps to influence, interact and/or support the microbiome. Nevertheless, the microbiome and microbiome-related diseases have become a more and more important aspect and induce a need for developing microbiome-related treatments of diseases and health conditions. Atopic dermatitis (AD) for instance is a multifunctional complex disorder with various genetic risk factors but significant environmental triggers. AD is associated with a physical barrier defects and/or dysbioses (microbial imbalance). Patients exhibit suppression of various AMPs like Cathelicidin or ß-Defensin or alternations in T-cell homeostasis. The combination of antimicrobial and physical barrier defects likely pushes the dysbiosis leading to further disruption of the cellular immunity ba